You are here

Article Text

Article menu
Download PDFPDF
Mailbox
Macular infarction after intravitreal amikacin: authors’ reply
  1. G D Galloway,
  2. A Ramsay,
  3. K Jordan,
  4. A Vivian
  1. Addenbrooke’s Hospital, Cambridge, UK
  1. Correspondence to: G D Galloway Addenbrooke’s Hospital, Cambridge, UK; gavgaldoctors.net.uk

https://doi.org/10.1136/bjo.2004.042838

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Doft et al for their useful and expert opinion.1 The choice of which agent to use to empirically treat Gram negative organisms implicated in endophthalmitis remains controversial. As amikacin has been proved to cause macular infarction, we think one should look at viable alternatives. Ceftazidime is already in widespread use in the United Kingdom and appears not …

    View Full Text